Seizure News and Research

Latest Seizure News and Research

Anti-seizure drugs may increase risk of cardiovascular problems

An important clinical repercussion in the treatment of epilepsy has been discovered by a research team led by Scott Mintzer, M.D., assistant professor in the Department of Neurology and the Jefferson Comprehensive Epilepsy Center at Jefferson Medical College of Thomas Jefferson University.

20 Mar 2009

Stun guns can cause brain-specific complications such as seizures

Stun guns, in certain circumstances, may result in brain-specific complications such as seizures, according to a new case report published in CMAJ http://www.cmaj.ca/press/pg625.pdf.

16 Mar 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Search for blood pressure secrets reveals a surprising new syndrome

Yale researchers investigating the genetic causes of blood pressure variation have identified a previously undescribed syndrome associated with seizures, a lack of coordination, developmental delay and hearing loss.

16 Mar 2009

Cause of severe pediatric epilepsy disorder discovered

Researchers at the University of California, San Diego School of Medicine have discovered that convulsive seizures in a form of severe epilepsy are generated, not on the brain's surface as expected, but from within the memory-forming hippocampus.

16 Mar 2009

Obama hosts health care summit at White House

A White House health care summit hosted on Thursday by President Obama will enable attendees to discuss reform proposals for the U.S. health care system, the AP/Philadelphia Inquirer reports (Alonso-Zaldivar, AP/Philadelphia Inquirer, 3/5).

5 Mar 2009

Launch of new foundation for Batten disease

Leading scientists, medical researchers and affected families joined together today to launch Beyond Batten Disease Foundation, an organization committed to finding a cure for this rare disease that claims the lives of children.

4 Mar 2009

Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer

Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.

25 Feb 2009

Having health insurance essential for people's health and well-being

The evidence shows more clearly than ever that having health insurance is essential for people's health and well-being, and safety-net services are not enough to prevent avoidable illness, worse health outcomes, and premature death, says a new report from the Institute of Medicine.

24 Feb 2009

Significant Rett syndrome discovery

A paper published online today in Nature Neuroscience reveals the presence of methyl CpG binding protein 2 (MeCP2) in glia. MeCP2 is a protein associated with a variety of neurological disorders, including Rett Syndrome, the most physically disabling of the autism spectrum disorders.

23 Feb 2009

New test for mysterious metabolic diseases

Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism.

15 Feb 2009

UT Southwestern develops medically supervised liquid diet program

UT Southwestern Medical Center's bariatric program has developed a medically supervised program using a specially designed liquid protein diet for people looking to lose weight with or without surgery.

9 Feb 2009

Antiepileptic drug vigabatrin may decrease spasms for infants with epilepsy

The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatments against a special form of epilepsy in infants, called infantile spasm.

2 Feb 2009

Statins may treat cerebral cavernous malformation

In a finding that could save thousands of lives a year, University of Utah School of Medicine researchers have shown that a blood vessel disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis or other problems is treatable with the same statin drugs that millions of people take to control high cholesterol.

27 Jan 2009

More scientific evidence supporting Darwinian views of evolution

Studies at the University of Pennsylvania School of Medicine on brain electrical signaling offer a fresh perspective on vertebrate evolution, provide additional evidence supporting Darwinian views of evolution, and may also lead to more effective treatment of epileptic seizures in infants.

21 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Discovery of link between genetic defect on chromosome 15 and epilepsy

In a research published in the advanced online publication of the scientific magazine Nature Genetics, researchers have identified a genetic defect for common epilepsies on chromosome 15.

15 Jan 2009

Missing DNA the culprit in epilepsy?

An international team of scientists have identified a genetic risk factor for epilepsy which may lead to a better understanding of what causes the seizures and the development of new treatments for the condition.

12 Jan 2009

Repeat cesarean deliveries before 39 weeks raises risk of neonatal illness

Women choosing repeat cesarean deliveries and having them at term but before completing 39 weeks gestation are up to two times more likely to have a baby with serious complications including respiratory distress resulting in mechanical ventilation and NICU admission.

7 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009